Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097903
Status:
COMPLETED
Last Update Posted:
2020-03-12
First Post:
2004-12-01
Brief Title:
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
Sponsor:
BioNumerik Pharmaceuticals Inc
Organization:
BioNumerik Pharmaceuticals Inc
Study Overview
Official Title:
Phase 1 Trial of Oral Karenitecin in Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin BNP1350 in patients with solid tumors
Detailed Description:
Initially the safety side effects and recommended phase 2 dose of oral Karenitecin in patients with advanced solid tumors will be determined
When the recommended phase 2 dose has been determined the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer
When the recommended phase 2 dose has been determined the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None